Lenzilumab increases likelihood of survival among Black patients with COVID-19

Lenzilumab increases likelihood of survival among Black patients with COVID-19

Humanigen has announced that its antibody lenzilumab increased the likelihood of survival among certain Black and African American patients with COVID-19.Lenzilumab is a novel, first in-class product “that binds to and neutralizes granulocyte-macrophage colony-stimulating factor,” according to a company press release.The data on lenzilumab are from the phase 3 LIVE-AIR trial, which enrolled 520 adults from 29 sites in the United States and Brazil who experienced blood oxygen saturation of 94% or less; or needed low-flow supplemental oxygen, high-flow oxygen support or noninvasiveRead More

Share on facebook
Share on twitter
Share on linkedin